COVID-19 trials registries data warehouse

http://en.irct.ir/trial/49629

Mohsen Tafaghodi

tafaghodim@mums.ac.ir

2020-07-16

Completed

RCT

Randomized

Parallel

Blind label

single-center

Treatment

Laboratory or clinical diagnosis of COVID-19 with admission indication age between 18-65 y sign of the written consent not concomitant use of kaletra or other PIs, cyclosporine, colchicine, ciproterone, danazol, gemfibrozil, potent CYP3A4 inhibitors or inducers like macrolides, CCBs, Azoles, rifampin, phenytoin not using statin before including in the study

history of allergy to statins pregnancy and lactation active liver disease or rise of LFT during study including in other studies start of PIs ADR occurrence e.g. rhabdomyolysis severe renal failure (GFR<30 ml/min) indication for intubation or ICU not being able to swallow medication

2

Mashhad University of Medical Sciences

18

65

Iran

Mild/moderate disease at enrollment

2: Mild/moderate disease at enrollment

40

fever clinical response to treatment (including improvement of cough, myalgia, headache, Olfactory and taste disorders) radiologic response laboratory response drug adverse reaction

Phase 2

[{"arm_notes": "", "treatment_id": 137, "treatment_name": "Atorvastatin", "treatment_type": "Metabolic agents", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "", "treatment_id": 2187, "treatment_name": "Placebo", "treatment_type": "Placebo", "pharmacological_treatment": "Placebo"}]